Biomarkers for Systemic Therapy in Metastatic Breast Cancer
Key Points
Key Points
Testing for ESR1, PIK3CA, AKT1 and inactivation of PTEN somatic variants and germline BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) pathogenic variants (mutations) to guide therapy.
Testing tumors for homologous recombination deficiency, expression of programmed cell death ligand-1 (PD-L1), deficient mismatch repair microsatellite instability (dMMR/MSI), tumor mutational burden (TMB), neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and trophoblast cell-surface antigen 2 (TROP2) expression to determine eligibility for selected treatments.
The use of cell-free, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for monitoring treatment response.
Treatment
...atment...
...ndations from 2024 Rapid Recommendation Upda...
...ation 1.1The Expert Panel recommends multiple...
...endation 1.2There are no comparative efficac...
...reatment Options According to Prior Endocr...
...ons from 2023 Rapid Recommendation...
...o aid in treatment selection, the Expert Pan...
...previously treated with ET and a CD...
...ions from 2022 Focused Guideline Update...
Recommendation 1.1Patients with locally recurrent...
...mmendation 3.1Patients with metastatic HER2-ne...
...endation 3.2There is insufficient evidence...
...tion 4.1There are insufficient data a...
...mendation 5.1Patients with locally recurrent u...
....1Patients with metastatic cancer who are candi...
...7.1Patients with metastatic cancer who are c...
...tion 8.1Clinicians may test for NTRK fusions in...
...on 9.1There are insufficient data to recomm...
...10.1There are insufficient data to r...
...endation 11.1There are insufficient data to recomm...
...Unchanged From 2015 Guideline...
...itial presentation of metastasis from breast can...
...ommendation for Tissue Biomarke...
...patients who are already receiving...
...ations for Circulating Tumor Ma...
...atients already receiving systemic therapy fo...
...noembryonic antigen (CEA), cancer antigen...
...-Glance Guide to ASCO Biomarker Testing...
...Tests Recommended by the ASCO Expert PanelHavi...
...ests Not Recommended by the ASCO Expert P...
...-Glance Guide to ASCO Biomarker Te...
...-A-Glance Guide to ASCO Biomarker Testing...
...ASCO believes that cancer clinical trials...